ArticleFuture oncology (London, England)2025
Real-world treatment patterns and attrition for non-driver mutation metastatic non-small cell lung cancer in the US.
Article in Future oncology (London, England), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
aimsProgrammed cell death protein-1/ligand-1 (PD-1/PD-L1) inhibitors (PD-[L]1) are standard of care for patients with metastatic non-small cell lung cancer (mNSCLC). This study examined real-world treatment patterns and attrition by lines of therapy (LOTs) among patients with non-driver mutation mNSCLC. PATIENTS &
methodsA retrospective study of adult patients with mNSCLC (2015‒2022) who received ≥1 systemic treatment in COTA's United States multicenter NSCLC database was conducted. Treatment patterns, duration, and outcomes were summarized descriptively. PD-(L)1 utilization was stratified by PD-L1 expression levels (<1%, 1%‒49%, ≥50%).
resultsAmong the 2,107 eligible patients, PD-(L)1-based therapy was the most common frontline therapy (55.8%); of these, 60.5% received PD-(L)1/platinum combination therapy. Among PD-(L)1 users, frontline PD-(L)1 monotherapy was most frequently utilized in patients with PD-L1 expression ≥50% (66.2%). Utilization of frontline platinum chemotherapy without PD-(L)1 decreased from 76.8% (2015) to <15% (2019-2022). Mortality across LOTs 1-4 was 37.4%-42.2% and attrition was approximately 60% for each LOT. The overall median duration of LOT1 was 5.4 months. A decreasing trend in the treatment and LOT duration of subsequent LOTs was observed.
conclusionsDespite incorporating PD-(L)1-based therapies for frontline mNSCLC, mortality and attrition during LOT1 remained high and therapy duration was short, reflecting challenges in managing mNSCLC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.